Arevipharma

Executive Summary

Arevipharma GmbH is a German contract development and manufacturing organization (CDMO) that specializes in the custom synthesis and cGMP production of active pharmaceutical ingredients (APIs). Located in Radebeul, the company leverages a legacy of chemical synthesis dating back to 1874, enabling it to offer decades of expertise in handling complex molecules. It focuses heavily on controlled substances, particularly narcotics, as well as advanced intermediates for oncology and immunology therapeutics. This niche positioning allows Arevipharma to serve clients requiring stringent regulatory compliance and high potency manufacturing. Despite being founded in 2018, the company has quickly established itself by combining modern facilities with deep-rooted chemical synthesis capabilities. As a private entity, Arevipharma operates with limited public disclosure, but its strategic focus on high-demand, high-barrier sectors positions it for steady growth. The CDMO market is expanding, especially for specialized services like narcotic API production, due to increasing drug development complexity and outsourcing trends. Arevipharma's integrated site in Radebeul offers a competitive edge in cost efficiency and regulatory adherence. Future growth likely hinges on capacity expansions, new client partnerships, and broadening its controlled substance portfolio. While near-term visibility is low, the company's unique capabilities and historical expertise suggest a stable trajectory in the specialized CDMO landscape.

Upcoming Catalysts (preview)

• TBDExpansion of manufacturing capacity or new facility in EU70% success
• TBDStrategic partnership with a large pharma for narcotic API supply60% success
• TBDCertification for new controlled substance categories75% success